Prelude Therapeutics Inc (PRLD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $272.13M
Last updated: Nov 17, 2026 at 4:10 PM ET
Prelude Therapeutics Inc (PRLD) Statistics
Prelude Therapeutics (PRLD) has a market cap of $272.13M and an enterprise value of $248.72M. It kept -247.12% of revenue as net income over the last 12 months. Its share count is up 35.41% from a year earlier.
Total Valuation
Enterprise value is 8.60% below the market cap, as cash exceeds debt.
| Market Cap | $272.13M |
|---|---|
| Enterprise Value | $248.72M |
| Latest price (Nov 17, 2026) | $3.32 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 15.9x and 2.8x. Its year-end P/S ranged from 13.8x to 86.8x from 2023 to 2025.
| P/S Ratio | 15.9x |
|---|---|
| Forward P/S | 7.0x |
| P/B Ratio | 2.8x |
Price Statistics
The stock is up 118.42% over 52 weeks and trades 15.31% below its 50-day average.
| Beta (1Y) | 1.72 |
|---|---|
| 52-Week Change | +118.42% |
| 1-Month Change | -2.06% |
| 3-Month Change | -42.56% |
| 6-Month Change | -22.25% |
| 5-Year Change | -77.93% |
| Total Return (1Y) | +118.42% |
| Total Return (3Y CAGR) | -2.66% |
| Total Return (5Y CAGR) | -25.49% |
| Return vs SPY (1Y) | +86.06% |
| Max Drawdown (1Y) | -51.28% |
| Max Drawdown (3Y) | -90.42% |
| Sharpe Ratio (1Y) | 0.64 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $3.92 |
| 200-Day Average | $4.11 |
| 52-Week Range | $1.29 to $6.83 |
| RSI (14 Days) | 37.5 |
| Average Volume (20 Days) | 294.27K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.20x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.20x |
|---|---|
| Quick Ratio | 4.20x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -42.94% over the last 12 months, against a 5-year average of -78.24%.
| Return on Equity (ROE) | -42.94% |
|---|---|
| Return on Assets (ROA) | -30.38% |
| Return on Capital Employed (ROCE) | -37.66% |
| ROE (5Y Average) | -78.24% |
| ROA (5Y Average) | -55.14% |
| Asset Turnover | 0.16x |
Scores
PRLD has an Altman Z-Score of -1.88, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.88 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $21.57M over the last 12 months is up 105.44% from the 12 months before.
| Revenue | $21.57M |
|---|---|
| Revenue Growth (YoY) | +105.44% |
| Gross Profit | $21.57M |
| Operating Income | -$61.24M |
| Pretax Income | -$53.31M |
| Net Income | -$53.31M |
| EBITDA | -$53.21M |
| EBIT | -$53.31M |
| Reported EPS (TTM) | -$0.59 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 70.74% of the $175.49M in total assets.
| Cash and Equivalents | $23.41M |
|---|---|
| Total Debt | $0 |
| Net Cash | $23.41M |
| Net Cash Per Share | $0.23 |
| Working Capital | $108.50M |
| Shareholder Equity | $124.14M |
| Book Value Per Share | $1.20 |
| Total Assets | $175.49M |
| Total Liabilities | $51.35M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$27.92M |
|---|---|
| FCF Per Share | -$0.43 |
| Depreciation and Amortization | $2.91M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -283.92%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -283.92% |
| Pretax Margin | -247.12% |
| Net Margin | -247.12% |
| EBITDA Margin | -246.67% |
| EBIT Margin | -247.12% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -43.43% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -43.43% |
Dividends and Yields
PRLD does not pay a dividend.
| Buyback Yield | -5.91% |
|---|---|
| Shareholder Yield | -5.91% |
Peer Position
Against 6 similar companies, PRLD has the 2nd highest P/S.
P/S RatioPeer median 5.7x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -49.91%
| P/S Ratio | 15.9x vs 5.7x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +105.44% vs -49.91% median |
Analyst Forecast
Consensus estimates put revenue growth at 72.98% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +72.98% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PRLD
What is PRLD's market cap?
Prelude Therapeutics has a market cap of $272.13M. Its enterprise value, which adds debt and subtracts cash, is $248.72M.
How many shares of PRLD are outstanding?
Prelude Therapeutics has 103.09M shares outstanding. The count is up 35.41% from a year earlier.
Does PRLD pay a dividend?
No. Prelude Therapeutics does not pay a dividend.
How much debt does PRLD have?
Prelude Therapeutics has $0 of total debt and $23.41M of cash and equivalents, a net cash position of $23.41M.
PRLD pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors